Perspective Therapeutics (CATX) Free Cash Flow (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Free Cash Flow data on file, last reported at -$31.5 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 19.93% year-over-year to -$31.5 million; the trailing twelve-month figure through Mar 2026 stood at -$100.5 million (up 10.93% YoY), and the FY2025 full-year result was -$95.2 million, down 30.98% from the prior year.
• Free Cash Flow grew to -$31.5 million in Q1 2026, from -$37.3 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $13.8 million in Q1 2024 to a low of -$41.2 million in Q4 2024.
• A 5-year average of -$15.0 million and a median of -$10.3 million in 2023 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow slumped 584.41% in 2023 and surged 239.54% in 2024, its largest moves.
• Tracing CATX's Free Cash Flow over 5 years: stood at -$6.2 million in 2022, then tumbled by 45.86% to -$9.1 million in 2023, then sank by 353.12% to -$41.2 million in 2024, then rose by 9.46% to -$37.3 million in 2025, then increased by 15.69% to -$31.5 million in 2026.
• Business Quant data shows CATX's Free Cash Flow at -$31.5 million in Q1 2026, -$37.3 million in Q4 2025, and -$16.3 million in Q3 2025.